$QNCX
Quince Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023063716 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.909M $4.660M
YoY Change 38.28% 7.37%
% of Gross Profit
Research & Development $3.434M $1.431M
YoY Change 23.97% -41.62%
% of Gross Profit
Depreciation & Amortization $302.0K $0.00
YoY Change 655.0% -100.0%
% of Gross Profit
Operating Expenses $9.921M $6.094M
YoY Change 56.98% -20.03%
Operating Profit -$6.094M
YoY Change -20.03%
Interest Expense $1.014M $960.0K
YoY Change 87.78% 200.0%
% of Operating Profit
Other Income/Expense, Net $64.00K -$216.0K
YoY Change -74.4% -64.94%
Pretax Income -$8.843M -$5.350M
YoY Change 59.91% -32.45%
Income Tax $51.00K $0.00
% Of Pretax Income
Net Earnings -$8.894M -$5.351M
YoY Change 60.83% -32.45%
Net Earnings / Revenue
Basic Earnings Per Share -$0.15
Diluted Earnings Per Share -$0.22 -$0.15
COMMON SHARES
Basic Shares Outstanding 42.87M 36.38M
Diluted Shares Outstanding 36.07M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $75.06M $82.42M
YoY Change -16.77% -2.01%
Cash & Equivalents $20.75M $20.82M
Short-Term Investments $54.31M $61.59M
Other Short-Term Assets $81.00K $92.00K
YoY Change -70.65% -72.62%
Inventory
Prepaid Expenses $365.0K $270.0K
Receivables
Other Receivables
Total Short-Term Assets $77.44M $85.17M
YoY Change -17.4% -13.33%
LONG-TERM ASSETS
Property, Plant & Equipment $234.0K $5.000K
YoY Change -40.46% -98.67%
Goodwill $17.63M $0.00
YoY Change
Intangibles $63.67M $0.00
YoY Change 979.19% -100.0%
Long-Term Investments $78.00K $100.0K
YoY Change -97.83% -98.0%
Other Assets $8.456M $100.0K
YoY Change 488.24%
Total Long-Term Assets $90.46M $213.0K
YoY Change 790.18% -98.15%
TOTAL ASSETS
Total Short-Term Assets $77.44M $85.17M
Total Long-Term Assets $90.46M $213.0K
Total Assets $167.9M $85.39M
YoY Change 61.58% -22.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.033M $409.0K
YoY Change 256.67% -65.37%
Accrued Expenses $3.436M $1.844M
YoY Change 37.49% -51.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $9.572M $2.253M
YoY Change 211.89% -54.44%
LONG-TERM LIABILITIES
Long-Term Debt $13.43M $0.00
YoY Change
Other Long-Term Liabilities $587.0K
YoY Change
Total Long-Term Liabilities $587.0K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $9.572M $2.253M
Total Long-Term Liabilities $587.0K $0.00
Total Liabilities $82.82M $2.253M
YoY Change 2396.71% -57.05%
SHAREHOLDERS EQUITY
Retained Earnings -$319.6M -$310.8M
YoY Change 10.86% 9.94%
Common Stock $6.500M $393.4M
YoY Change -98.33% 1.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $85.08M $83.13M
YoY Change
Total Liabilities & Shareholders Equity $167.9M $85.39M
YoY Change 61.58% -22.22%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$8.894M -$5.351M
YoY Change 60.83% -32.45%
Depreciation, Depletion And Amortization $302.0K $0.00
YoY Change 655.0% -100.0%
Cash From Operating Activities -$6.082M -$4.810M
YoY Change 4.14% -28.1%
INVESTING ACTIVITIES
Capital Expenditures $20.00K $0.00
YoY Change -71.43% -100.0%
Acquisitions
YoY Change
Other Investing Activities $5.412M $3.640M
YoY Change -71.14% -141.46%
Cash From Investing Activities $5.392M $3.630M
YoY Change -71.1% -141.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 53.00K 10.00K
YoY Change -365.0%
NET CHANGE
Cash From Operating Activities -6.082M -4.810M
Cash From Investing Activities 5.392M 3.630M
Cash From Financing Activities 53.00K 10.00K
Net Change In Cash -637.0K -1.170M
YoY Change -104.98% -92.46%
FREE CASH FLOW
Cash From Operating Activities -$6.082M -$4.810M
Capital Expenditures $20.00K $0.00
Free Cash Flow -$6.102M -$4.810M
YoY Change 3.25% -28.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001662774
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q3 qncx Accumulated Amortization Of Finance Lease
AccumulatedAmortizationOfFinanceLease
CY2023Q3 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet
CY2022Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38890
dei Entity Registrant Name
EntityRegistrantName
Quince Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
90-1024039
dei Entity Address Address Line1
EntityAddressAddressLine1
601 Gateway Boulevard, Suite 1250.
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
415
dei Local Phone Number
LocalPhoneNumber
910-5717
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42868947
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21632000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44579000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
61593000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
45602000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1448000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3567000
CY2023Q3 qncx Notes Receivables Current
NotesReceivablesCurrent
500000
CY2022Q4 qncx Notes Receivables Current
NotesReceivablesCurrent
0
CY2023Q3 us-gaap Assets Current
AssetsCurrent
85173000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
93748000
CY2023Q3 qncx Assets Held For Sale Not Part Of Disposal Group Non Current
AssetsHeldForSaleNotPartOfDisposalGroupNonCurrent
82000
CY2022Q4 qncx Assets Held For Sale Not Part Of Disposal Group Non Current
AssetsHeldForSaleNotPartOfDisposalGroupNonCurrent
0
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
393000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
48000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
291000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
3578000
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
0
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5900000
CY2023Q3 qncx Equity Investments In Lighthouse Inc
EquityInvestmentsInLighthouseInc
78000
CY2022Q4 qncx Equity Investments In Lighthouse Inc
EquityInvestmentsInLighthouseInc
0
CY2023Q3 us-gaap Assets
Assets
85386000
CY2022Q4 us-gaap Assets
Assets
103910000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
409000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
570000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1844000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2499000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2253000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3069000
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
0
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
248000
CY2023Q3 us-gaap Liabilities
Liabilities
2253000
CY2022Q4 us-gaap Liabilities
Liabilities
3317000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36343632
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36343632
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36136480
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36136480
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
36000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
36000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
393331000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
389105000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
516000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-289000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-310750000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-288259000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
83133000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
100593000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
85386000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
103910000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1431000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2451000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6013000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22410000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4663000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4344000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12786000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22461000
CY2023Q3 qncx Goodwill Impairment Charge
GoodwillImpairmentCharge
0
CY2022Q3 qncx Goodwill Impairment Charge
GoodwillImpairmentCharge
825000
qncx Goodwill Impairment Charge
GoodwillImpairmentCharge
0
qncx Goodwill Impairment Charge
GoodwillImpairmentCharge
825000
CY2023Q3 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2022Q3 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
5900000
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
6094000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
7620000
us-gaap Operating Expenses
OperatingExpenses
24699000
us-gaap Operating Expenses
OperatingExpenses
45696000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6094000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7620000
us-gaap Operating Income Loss
OperatingIncomeLoss
-24699000
us-gaap Operating Income Loss
OperatingIncomeLoss
-45696000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
959000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
315000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2464000
us-gaap Investment Income Interest
InvestmentIncomeInterest
532000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-216000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-616000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-504000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1246000
CY2023Q3 us-gaap Income Loss Including Portion Attributable To Noncontrolling Interest
IncomeLossIncludingPortionAttributableToNoncontrollingInterest
-5351000
CY2022Q3 us-gaap Income Loss Including Portion Attributable To Noncontrolling Interest
IncomeLossIncludingPortionAttributableToNoncontrollingInterest
-7921000
us-gaap Income Loss Including Portion Attributable To Noncontrolling Interest
IncomeLossIncludingPortionAttributableToNoncontrollingInterest
-22739000
us-gaap Income Loss Including Portion Attributable To Noncontrolling Interest
IncomeLossIncludingPortionAttributableToNoncontrollingInterest
-46410000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-248000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-284000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5351000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7921000
us-gaap Net Income Loss
NetIncomeLoss
-22491000
us-gaap Net Income Loss
NetIncomeLoss
-46126000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
158000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
343000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
309000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
481000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
101000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-130000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
496000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-655000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5092000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7708000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21686000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46300000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.41
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.41
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36073040
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36073040
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35612749
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35612749
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35941234
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35941234
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32758132
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32758132
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
86884000
CY2023Q3 qncx Share Based Compensation Arrangement By Share Based Payment Award Value Options And Non Option Equity Instruments Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod
28000
CY2023Q3 qncx Stockissuedduringperiodvaluerestrictedstockawardretirement
Stockissuedduringperiodvaluerestrictedstockawardretirement
-18000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1331000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
158000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
101000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5351000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
83133000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
111532000
CY2022Q3 qncx Share Based Compensation Arrangement By Share Based Payment Award Value Options And Non Option Equity Instruments Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod
13000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
694000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
343000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-130000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7921000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
104531000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
100593000
qncx Share Based Compensation Arrangement By Share Based Payment Award Value Options And Non Option Equity Instruments Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod
110000
qncx Stockissuedduringperiodvaluerestrictedstockawardretirement
Stockissuedduringperiodvaluerestrictedstockawardretirement
-18000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4134000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
309000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
496000
us-gaap Net Income Loss
NetIncomeLoss
-22491000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
83133000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
118586000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
608000
qncx Share Based Compensation Arrangement By Share Based Payment Award Value Options And Non Option Equity Instruments Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod
148000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14986000
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
16503000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
481000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-655000
us-gaap Net Income Loss
NetIncomeLoss
-46126000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
104531000
us-gaap Profit Loss
ProfitLoss
-22491000
us-gaap Profit Loss
ProfitLoss
-46126000
us-gaap Share Based Compensation
ShareBasedCompensation
4134000
us-gaap Share Based Compensation
ShareBasedCompensation
14986000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
18000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
162000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
66000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
136000
qncx Loss On Disposal
LossOnDisposal
71000
qncx Loss On Disposal
LossOnDisposal
77000
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
78000
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
0
qncx Non Cash Goodwill Impairment Charge
NonCashGoodwillImpairmentCharge
0
qncx Non Cash Goodwill Impairment Charge
NonCashGoodwillImpairmentCharge
825000
qncx Non Cash Intangible Impairment Charge
NonCashIntangibleImpairmentCharge
5900000
qncx Non Cash Intangible Impairment Charge
NonCashIntangibleImpairmentCharge
0
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1313000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-83000
qncx Change In Deferred Tax Liabilities Due To Acquisition
ChangeInDeferredTaxLiabilitiesDueToAcquisition
248000
qncx Change In Deferred Tax Liabilities Due To Acquisition
ChangeInDeferredTaxLiabilitiesDueToAcquisition
284000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2272000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2396000
qncx Increase Decrease In Right Of Use Assets And Lease Liabilities
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilities
-192000
qncx Increase Decrease In Right Of Use Assets And Lease Liabilities
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilities
0
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
0
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-175000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-161000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5329000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-576000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-5304000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12214000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38203000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
95116000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
66767000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
84514000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
55495000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
10593000
qncx Payments To Acquire Notes Receivable1
PaymentsToAcquireNotesReceivable1
500000
qncx Payments To Acquire Notes Receivable1
PaymentsToAcquireNotesReceivable1
0
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
90000
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
70000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
136000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
55000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11148000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-664000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
6000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
31000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
92000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
148000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
608000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
86000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
725000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
329000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
227000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22947000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-37915000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44579000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69724000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21632000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31809000
us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
0
us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
16503000
qncx Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities1
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities1
0
qncx Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities1
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities1
256000
qncx Right Of Use Asset And Financing Lease Liability Reduction As A Result Of Lease Modification
RightOfUseAssetAndFinancingLeaseLiabilityReductionAsAResultOfLeaseModification
-70000
qncx Right Of Use Asset And Financing Lease Liability Reduction As A Result Of Lease Modification
RightOfUseAssetAndFinancingLeaseLiabilityReductionAsAResultOfLeaseModification
0
qncx Right Of Use Asset And Operating Lease Liability Reduction As A Result Of Lease Modification
RightOfUseAssetAndOperatingLeaseLiabilityReductionAsAResultOfLeaseModification
0
qncx Right Of Use Asset And Operating Lease Liability Reduction As A Result Of Lease Modification
RightOfUseAssetAndOperatingLeaseLiabilityReductionAsAResultOfLeaseModification
-640000
qncx Entity Date Of Incorporation
EntityDateOfIncorporation
2012-06
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-310800000
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
83200000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:8%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses, as well as related disclosure of contingent assets and liabilities. The most significant estimates used in the Company’s consolidated financial statements relate to the determination of the fair value of stock-based awards and other issuances, determination of the fair value of identifiable assets and liabilities in connection with the acquisition of Novosteo, Inc., including associated intangible assets and goodwill, accruals for research and development costs, useful lives of long-lived assets, stock-based compensation and related assumptions, the incremental borrowing rate for leases and income tax uncertainties, including a valuation allowance for deferred tax assets, eligibility of expenses for the Australia research and development refundable tax credits, impairment of intangible assets or goodwill, collectability of note receivable; and contingencies. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from the Company’s estimates.</span></p>
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2023Q3 qncx Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2023Q3 qncx Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2022Q4 qncx Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
0
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
61593000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
61593000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
82416000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
89773000
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
82477000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
65000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
82416000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20823000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
61593000
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
82416000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
90330000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
562000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
89773000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40593000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
45602000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
3578000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
89773000
qncx Weighted Average Remaining Contractual Maturities Of Available For Sale Securities
WeightedAverageRemainingContractualMaturitiesOfAvailableForSaleSecurities
P3M
CY2023Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
22662000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
5000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
5151000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
60000
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
27813000
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
65000
CY2023Q3 qncx Available For Sale Securities Gross Realized Gains Or Losses
AvailableForSaleSecuritiesGrossRealizedGainsOrLosses
0
qncx Available For Sale Securities Gross Realized Gains Or Losses
AvailableForSaleSecuritiesGrossRealizedGainsOrLosses
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2023Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
21632000
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
44579000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
61593000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
45602000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
3578000
CY2023Q3 us-gaap Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Cumulative Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount
0
CY2023Q3 us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Cumulative Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount
0
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
270000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
223000
CY2023Q3 qncx Prepaid Insurance Current
PrepaidInsuranceCurrent
1037000
CY2022Q4 qncx Prepaid Insurance Current
PrepaidInsuranceCurrent
977000
CY2023Q3 qncx Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
49000
CY2022Q4 qncx Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
1088000
CY2023Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards Foreign
DeferredTaxAssetsTaxCreditCarryforwardsForeign
0
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Foreign
DeferredTaxAssetsTaxCreditCarryforwardsForeign
1003000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
92000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
276000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1448000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3567000
CY2023Q3 qncx Reductions In Research And Development Expense
ReductionsInResearchAndDevelopmentExpense
0
qncx Reductions In Research And Development Expense
ReductionsInResearchAndDevelopmentExpense
0
CY2022Q3 qncx Reductions In Research And Development Expense
ReductionsInResearchAndDevelopmentExpense
100000
qncx Reductions In Research And Development Expense
ReductionsInResearchAndDevelopmentExpense
500000
qncx Schedule Of Notes Receivable
ScheduleOfNotesReceivable
<p style="text-indent:8%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes receivables consist of the following (in thousands):</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:35.122%;"></td> <td style="width:5.707%;"></td> <td style="width:1%;"></td> <td style="width:26.212999999999997%;"></td> <td style="width:1%;"></td> <td style="width:4.105%;"></td> <td style="width:1%;"></td> <td style="width:24.852%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="border-top:0.5pt solid #000000;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span></p></td> <td style="border-top:0.5pt solid #ffffff03;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="border-top:0.5pt solid #000000;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span></p></td> <td style="border-top:0.5pt solid #ffffff03;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes receivable</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">500</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total Notes receivable</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">500</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table><p style="text-indent:8%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 30, 2023, EryDel Italy, Inc., an indirect wholly owned subsidiary of the Company, entered into that certain promissory note, (the “Promissory Note”) with EryDel S.p.A. (“EryDel”), pursuant to which EryDel Italy, Inc. promised to make advances to EryDel of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
500000
CY2022Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
0
CY2023Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
500000
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
0
CY2023Q3 qncx Assets Held For Sale
AssetsHeldForSale
82000
CY2022Q4 qncx Assets Held For Sale
AssetsHeldForSale
0
CY2023Q3 qncx Consignment Equipment
ConsignmentEquipment
100000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
185000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
393000
CY2023Q3 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
1366000
CY2022Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
1130000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
225000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
234000
CY2023Q3 qncx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
41000
CY2022Q4 qncx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
497000
CY2023Q3 qncx Accrued Operating Lease Liabilities Current
AccruedOperatingLeaseLiabilitiesCurrent
61000
CY2022Q4 qncx Accrued Operating Lease Liabilities Current
AccruedOperatingLeaseLiabilitiesCurrent
377000
CY2023Q3 qncx Accrued Finance Lease Liabilities Current
AccruedFinanceLeaseLiabilitiesCurrent
0
CY2022Q4 qncx Accrued Finance Lease Liabilities Current
AccruedFinanceLeaseLiabilitiesCurrent
76000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
151000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
185000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1844000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2499000
CY2022Q4 qncx Accrued Severance
AccruedSeverance
0
qncx Accrued Severance Incurred
AccruedSeveranceIncurred
770000
qncx Accrued Severance Paid
AccruedSeverancePaid
-309000
CY2023Q3 qncx Accrued Severance
AccruedSeverance
461000
CY2023Q3 us-gaap Severance Costs1
SeveranceCosts1
475000000
CY2023Q3 qncx Additional Cash Bonous Severance Percentage
AdditionalCashBonousSeverancePercentage
1
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
0.50
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
140000000
qncx Operating Lease Future Rent Expense
OperatingLeaseFutureRentExpense
48000000
qncx Finance Lease Amortized Period On Equipment Service
FinanceLeaseAmortizedPeriodOnEquipmentService
P18M
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
6000000
CY2023Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
70000000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
48000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
291000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
61000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
377000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
61000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
377000
CY2023Q3 qncx Finance Lease Right Of Use Asset Gross
FinanceLeaseRightOfUseAssetGross
0
CY2022Q4 qncx Finance Lease Right Of Use Asset Gross
FinanceLeaseRightOfUseAssetGross
124000
CY2022Q4 qncx Accumulated Amortization Of Finance Lease
AccumulatedAmortizationOfFinanceLease
50000
CY2023Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
0
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
74000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y2M12D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y10M24D
CY2022Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.067
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0571
CY2023Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0
CY2022Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0445
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
62000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
388000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
62000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
388000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
11000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
61000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
377000
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3800000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M13D
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1331000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
694000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4134000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14986000
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
262000
CY2022Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-7921000
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-47057000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7672237
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9038850
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
10593000
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
1040000
CY2022Q2 qncx Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Right Of Use Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets
124000
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
279000
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
5900000
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
1726000
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
532000
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
15678000
CY2022Q2 us-gaap Goodwill
Goodwill
825000
CY2022Q3 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
0
CY2023Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
5900000
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
5900000
CY2023Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
0
CY2023Q1 qncx Non Cash Goodwill Impairment Charge
NonCashGoodwillImpairmentCharge
5900000
CY2023Q3 us-gaap Goodwill
Goodwill
0
CY2022Q4 us-gaap Goodwill
Goodwill
0
CY2022 qncx Non Cash Goodwill Impairment Charge
NonCashGoodwillImpairmentCharge
800000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
6500000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
qncx-20230930_cal.xml Edgar Link unprocessable
qncx-20230930_def.xml Edgar Link unprocessable
0000950170-23-063716-index-headers.html Edgar Link pending
0000950170-23-063716-index.html Edgar Link pending
0000950170-23-063716.txt Edgar Link pending
0000950170-23-063716-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img245295508_0.jpg Edgar Link pending
img246219029_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
qncx-20230930.htm Edgar Link pending
qncx-20230930.xsd Edgar Link pending
qncx-ex10_2.htm Edgar Link pending
qncx-ex10_3.htm Edgar Link pending
qncx-ex10_4.htm Edgar Link pending
qncx-ex31_1.htm Edgar Link pending
qncx-ex31_2.htm Edgar Link pending
qncx-ex32_1.htm Edgar Link pending
qncx-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
qncx-20230930_lab.xml Edgar Link unprocessable
qncx-20230930_pre.xml Edgar Link unprocessable
qncx-20230930_htm.xml Edgar Link completed
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending